HLX3902 is a STEAP1×CD3×CD28 trispecific T‑cell engager developed as a potential first‑in‑class immunotherapy for prostate cancer. Prostate tumors are largely “cold” from an immunological standpoint. The microenvironment is immunosuppressive, T cells are scarce inside the tumor mass, and those that do infiltrate often burn out quickly after activation. Classical CD3‑only bispecific TCEs can force T […]
Chemical‑induced proximity (CIP) strategies have expanded the therapeutic toolbox by modulating protein–protein interactions, but classical approaches such as PROTACs and molecular glues often force unnatural pairings or stabilize existing interfaces, leading to variable or unpredictable effects. Domain‑ALTeration Chimeras (DALTACs) take a different path: instead of degrading targets or reinforcing native contacts, they selectively miswire endogenous […]
A new experimental drug called TBI‑001 targets a protein called TRIB2 in advanced prostate cancer that has become resistant to hormone therapy and starts acquiring neuroendocrine features. This is particularly relevant for treatment‑emergent neuroendocrine prostate cancer (t‑NEPC), a lethal subtype that arises after long‑term androgen‑receptor–targeted therapy, loses dependence on AR signaling, and adopts a neuroendocrine […]
Most prostate cancer treatments today target the part of the AR protein that binds hormones, known as the ligand‑binding domain or LBD. At first these drugs like enzalutamide and abiraterone can shrink tumors or slow progression, but over time the cancer adapts and becomes resistant. This adaptation is a major reason why men with mCRPC […]
Cancer drugs like docetaxel work against prostate, lung, and other cancers, but they hit the whole body and often do not fully wake up the immune system. In this study, the research team built tiny nanoparticles (about 100–120 nm across) that carry docetaxel plus a light‑activated dye (IR808) and are made to open mainly inside […]
Researchers at Duke University have developed a new ultrasound‑based method called SonoPIN (“Sonoporation‑assisted Precise Intracellular Nanodelivery”) that helps large anticancer molecules get inside tumor cells with high precision, while causing minimal damage to healthy tissue. In early lab experiments, the technique killed about half of the targeted cancer cells, while more than 99% of non‑targeted […]
Scientists have developed a promising new CAR‑T cell therapy for osteosarcoma, the most common bone cancer in children, adolescents, and young adults, and the work carries a cautiously optimistic signal for other solid tumors, including metastatic prostate cancer. In a preclinical study, researchers at Case Western Reserve University and University Hospitals engineered T cells to […]
A new preclinical study shows how a simple tissue sample can be turned into a powerful tool for understanding and treating advanced prostate cancer. Researchers have developed a method to grow patient‑derived organoids from prostate tissue fragments removed during routine transurethral resection of the prostate, or TUR‑P, a common procedure often done for urinary symptoms. […]
Scientists have discovered that a simple mix of three amino acids can greatly improve how well lipid‑nanoparticle (LNP)–based therapies work in the body. These LNPs are tiny fat‑like packages used to carry mRNA or CRISPR components into cells, and they are already at the heart of new vaccines and gene‑editing treatments. The new finding suggests […]
Since October 2025, when the pre|CISION platform first demonstrated its potential to deliver dual payloads like MMAE and exatecan from a single molecule in prostate cancer models, significant new data has emerged that strengthens its case as a next-generation targeted therapy. The platform’s ability to exploit fibroblast activation protein (FAP) in the tumor microenvironment for […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy